Genelux Corporation (GNLX) Monday announced that it has named Matthew Pulisic as its new Chief Financial Officer, effective January 30.
With 19 years of global biopharma experience, previously Pulisic served as Vice President of Finance at Arrowhead
Pharmaceuticals, a publicly traded RNAi technology company.
GNLX is currently trading at $3.43 down 11.47 percent or $0.52 on the Nasdaq.
For comments and feedback: editorial@rttnews.com